Background: The intense inflammatory reaction following reperfusion of ischemic myocardium has been implicated as a factor in the extension of myocardial injury. One of the therapeutic goals of modem cardiology is to design strategies to limit the infarct size following myocardial infarction. A sound understanding of the inflammatory cascade that involves the release of various proinflammatory mediators from cardiac cells is necessary before a specific intervention is pursued.Observation: Summarized is the role of resident cardiac mast cells, which are noted to release inflammatory mediators, in ischemia-reperfusion-induced myocardial injury. Various pharmacologic interventions, such as disodium cromoglycate and ketotifen, that stabilize cardiac mast cells, or agents such as chlorpheniramine and cetirizine that prevent their degranulation during ischemia and reperfusion, may prove to be potential therapeutic agents to limit or salvage ischemia-reperfusion-induced injury.Conclusion: On the basis of the effects of histamine H1 antagonists, adrenoceptor blockers, cellular calcium and nitric oxide modulators, as well as inhibitors of phosphodiesterase and mitogen-activated protein kinase on mast cells, cardiac resident mast cells may represent a novel target for the development of cardioprotective agents.
2. Topol EJ, Weiss JL, Guzman P, et al. Immediate improvement of dysfunctional myocardial segments after coronary vascularization: Detection by intraoperative transesophageal echocardiography. J Am Coll Cardiol4:1123-1123, 1984
3.
3. Fransen EJ, Maessen JG, Hermens WT, et al. Peri-operative myocardial tissue injury and the release of inflammatory mediators in coronary bypass graft patients. Cardiovasc Res45:853-853, 2000
4.
4. Leiboff RH, Katz RN, Wasserman AG, et al. A randomized angiographically controlled trial of intracoronary streptokinase in acute myocardial infarction. Am J Cardiol53:404-404, 1984
5.
5. Rentrop KP. Thrombolytic therapy in patients with acute myocardial infarction. Circulation71:627-627, 1985
6.
6. Braunwald E, Kloner RA. Myocardial reperfusion: A double edged sword?J Clin Invest76:1713-1713, 1985
7.
7. Lucchesi BR. Complement neutrophils and free radicals: Mediators of reperfusion injury. Arzeimittel-Forschung44:420-420, 1994
8.
8. Grech ED, Jackson MJ, Ramsdale DR. Reperfusion injury after acute myocardial infarction. Br Med J310:477-477, 1995
10. Coombs VJ, Black L, Townsend SN. Myocardial reperfusion injury: The critical challenge. Crit Care Nurs Clin North Am4:339-339, 1992
11.
11. Bolli R.Mechanism of myocardial “stunning”. Circulation82:723-723, 1990
12.
12. Hess ML, Kukreja RC. Free radicals calcium homeostasis, heat shock proteins and myocardial stunning. Ann Thorac Surg60:760-760, 1995
13.
13. Forman MB, Puett DW, Virmani R.Endothelial and myocardial injury during ischemia and reperfusion: Pathogenesis and therapeutic implications. J Am Coll Cardiol13:450-450, 1989
14.
14. Steenbergen C, Hill ML, Jennings RB. Volume regulation and plasma membrane injury in aerobic, anaerobic and ischemic myocardium in vitro. Circ Res57:864-864, 1985
15.
15. Bond JM, Chacon E, Herman B, Lemasters JJ. Intracellular pH and Ca2+ homeostasis in pH paradox of reperfusion injury to neonatal rat cardiac myocytes. Am J Physiol265:C129-C129, 1993
16.
16. Jennings RB, Ganote CE, Reimer KA. Ischemic tissue injury. Am J Pathol81:179-179, 1975
17.
17. Jennings RB, Hawkins HKK, Lowe JE, Hill MC, Reimer KA. Relation between high-energy phosphate and lethal injury in myocardial ischemia in dogs. Am J Pathol92:187-187, 1978
18.
18. Burton KP, Morris AC, Massey KD, et al. Free radicals alter ionic calcium levels and membrane phospholipids in cultured rat ventricular myocytes. J Mol Cell Cardiol22:1035-1035, 1990
19.
19. Korthuis RJ, Granger DN. Reactive oxygen metabolites, neutrophils and the pathogenesis of ischemictissue/reperfusion. Clin Cardiol16 (Suppl 1): 119-119, 1993
20.
20. Ambrosio G, Villari B, Chiariello M.Calcium antagonists and experimental myocardial ischemia and reperfusion. J Cardiovasc Pharmacol20 (Suppl 7):S26-S26, 1992
21.
21. Yamamoto S, Matsui K, Kitano M, Ohashi N.SM-20550, a new Na+-H+ exchange inhibitor and its cardioprotective effect in ischemic-reperfused isolated rat hearts by preventing Ca2+ overload. J Cardiovasc Pharmacol35:855-855, 2000
22.
22. Mehta JL, Nichols WW, Mehta P.Neutrophils as potential participants in acute myocardial ischemia. J Am Coll Cardiol11:1309-1309, 1988
23.
23. Entman ML, Smith CW. Post reperfusion inflammation: A model for reaction to injury in cardiovascular disease. Cardiovasc Res28:1301-1301, 1994
24.
24. Valen G, Paulsson G, Vaage J.Induction of inflammatory mediators during reperfusion of the human heart. Ann Thorac Surg71:226-226, 2001
25.
25. Lucchesi BR, Mullane KM. Leukocytes and ischemia induced myocardial injury. Ann Rev Pharmacol Toxicol26:201-201, 1986
26.
26. Formigli L, Manneschi LI, Nediani C, et al. Are macrophages involved in early myocardial reperfusion injury?Ann Thorac Surg71:1596-1596, 2001
27.
27. Keller AM, Clancy RM, Barr ML, et al. Acute reoxygenation injury in the isolated rat heart: Role of resident cardiac mast cells. Circ Res63:1049-1049, 1988
28.
28. Parikh V, Singh M.Cardiac mast cell stabilization and cardioprotective effect of ischemic preconditioning in isolated rat heart. J Cardiovasc Pharmacol31:779-779, 1998
29.
29. Lazarus B, Messina A, Barker JE, et al. The role of mast cells in ischemia and reperfusion injury in skeletal muscles. J Pathol191:443-443, 2000
30.
30. Mukundan C, Gurish MF, Austen KF, et al. Mast cellmediation of muscle and pulmonary injury following hindlimb ischemia-reperfusion. J Histochem Cytochem49:1055-1055, 2000
31.
31. Rydzynski K, Dalen H, Saetersdal T, Engadal H.Morphologic and morphometic analysis of mast cells from human heart biopsies. Agents Actions20:288-288, 1987
32.
32. Sperr WR, Bankl HC, Mundigler G, et al. The human cardiac mast cell: Localization, isolation, phenotype and functional characterization. Blood84:3876-3876, 1994
33.
33. Marone G, de Crescenzo G, Adt M, et al. Immunological characterization and functional importance of human heart mast cells. Immunopharmacology31:1-1, 1995
34.
34. Patella V, de Crescenzo G, Ciccarelli A, et al. Human heart mast cells: A definitive case of mast cell heterogeneity. Int Arch Allergy Immunol106:386-386, 1995
35.
35. Irani AA, Schechter NM, Craig SS, et al. Two human mast cell subsets with distinct neutral protease compositions. Proc Natl Acad Sci USA83:4464-4464, 1986
36.
36. Irani AA, Bradford TR, Kepley CL, et al. Detection of MC-T and MC-TC types of human mast cells by immunohistochemistry using new monoclonal antitryptase and anti-chymase antibodies. J Histochem Cytochem37:1509-1509, 1989
37.
37. Weidener N, Austen KF. Heterogeneity of mast cells at multiple sites. Path Res Pract189:156-156, 1993
38.
38. Flint KC, Leung KBP, Pearce FL, et al. Human mast cells recovered by bronchoalveolar lavage: Their morphology, histamine release and the effects of sodium cromoglycate. Clin Sci68:427-427, 1985
39.
39. Proctor GB, Chann KM, Garrett JR, Smith RE. Proteinase activity in bovine atrium and possible role of mast cell tryptase in the processing of atrial natriuretic factor. Comb Biochem Physiol99:839-839, 1991
40.
40. Compton SJ, Cairns JA, Holgate SJ, Walls AF. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release and adhesion molecule expression: Tryptase induces expression of mRNA for ILI beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J Immunol161:1939-1939, 1998
41.
41. Urata H, Nishimura H, Ganten D.Mechanism of angiotensin II formation in humans. Eur Heart J16:79-79, 1995
42.
42. Daeman MJ, Urata H.Healing human myocardial infarction associated with increased chymase immunoreactivity. Heart Vessels12 (Suppl): 113-113, 1997
43.
43. Wypij DM, Nichols JS, Navak PJ, et al. Role of mast cell chymase in the extracellular processing of big endothelin I to endothelin I in perfused rat lung. Biochem Pharmacol43:845-845, 1992
44.
44. Yurt RW, Leid RW Jr, Austen KF, Silbert JE. Native heparin from rat peritoneal mast cells. J Biol Chem252:518-518, 1977
45.
45. Pejler G, Karlstorm A.Thrombin is inactivated by mast cell secretory chymase. J Biol Chem268:11817-11817, 1993
46.
46. Klein IM, Lavker RM, Matis WI, Murphy GK. Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci USA86:8972-8972, 1989
47.
47. Walsh IJ, Trichieri G, Waldorf H, et al. Human dermal mast cells contain and release tumour necrosis factoralpha which induces endothelial leukocyte adhesion molecule-i. Proc Natl Acad Sci USA88:4220-4220, 1991
48.
48. Bankl HC, Radaszkiewicz T, Klappacher GW, et al. Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit-ligand. Circulation91:275-275, 1995
49.
49. Koskinen PK, Kovanen PT, Lindstedt KA, Lemstrom KB. Mast cells in acute and chronic rejection of rat cardiac allografts-a major source of basic fibroblast growth factor. Transplantation71:1741-1741, 2001
50.
50. Zweifel M, Hirsiger H, Matozan K, et al. Mast cells in ongoing acute rejection: Increase in number and expression of a different phenotype in rat heart transplants. Transplantation73:1707-1707, 2002
51.
51. Zong ZP, Matsui S, Li AL, et al. Growth hormone interferes with the progression of myocarditis in rats. Eur J Pharmacol415:51-51, 2001
52.
52. Patella V, Marino I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation97:971-971, 1998
53.
53. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med195:375-375, 2002
54.
54. Cuculo A, Summaria F, Schiavino D, et al. Tryptase levels are elevated during spontaneous episodes in unstable angina but not after the ergonovine test in variant angina. Cardiologia43:189-189, 1998
55.
55. Laine P, Kaartinen M, Penttila A, et al. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation99:361-361, 1999
56.
56. Panizo A, Mirdan FJ, Galindo MF, et al. Are mast cells involved in hypertensive heart diseases?J Hypertens13:1201-1201, 1995
57.
57. Norrby K.Mast cells and angiogenesis. APMIS110:355-355, 2002
58.
58. Jolly SR, Abrams GD, Romson JL, et al. Effects of lodoxamide on ischemic reperfused myocardium. J Cardiovasc Pharmacol4:441-441, 1982
59.
59. Frangogiannis NG, Lindsey ML, Michael LH, et al. Residual cardiac mast cell degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation98:699-699, 1998
60.
60. Schiller S, Dorfman A.The isolation of heparin from mast cells of normal rat. Biochem Biophys Acta31:278-278, 1959
61.
61. Nagata K, Fujimiya M, Sugiura H, Uehara M.Intracellular localization of serotonin in mast cells of the colon in normal and colitis rats. Histochem J33:559-559, 2001
63. Fukuishi N, Sakaguchi M, Matsuura S, et al. The mechanisms of compound 48/80-induced superoxide generation mediated by A-kinase in rat peritoneal mast cells. Biochem Mol Med61:107-107, 1977
64.
64. Henderson WR, Kaliner M.Immunologic and nonimmunologic generation of superoxide from mast cells and basophils. J Clin Invest61:196-196, 1978
65.
65. Galli SJ, Lichtenstein LM. Biology of mast cells and basophils. In Middleton EJ, Reed CE, Ellis EF (eds). Allergy: Principles and Practice. St Louis-Principles and Practice. St Louis, Mosby, pp106-134, 1988
66.
66. Plaunt M, Pierce HJ, Watson CJ. Mast Cells lines produce lymphokines in response to cross linkage of FCeRI or to calcium ionophores. Nature339:64-64, 1989
67.
67. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/ cachectin. Nature346:274-274, 1990
68.
68. Gordon JR, Galli SJ. Mast cells as a source of multifunctional cytokines. Immunol Today11:458-458, 1990
69.
69. Teshima R, Onose J, Okunuki H, Sawada J.Effect of Ca (2+) ATPase inhibitors on MCP1 release from bone marrow derived mast cells and the involvement of p38 MAPK activation. Int Arch Allergy Immunol121:34-34, 2000
70.
70. Tosaki A, Bagchi D, Hellegouarch A, et al. Comparison of ESR and HPLC methods for the detection of hydroxyl radicals in ischemic/reperfusion hearts. A relationship between the genesis of oxygen-free radicals and reperfusion induced arrythmias. Biochem Pharmacol45:961-961, 1993
71.
71. Kramer JH, Misik V, Weglicki WB. Lipid peroxidationderived free radical production and postischemic myocardial reperfusion injury. Annal NY Acad Sci723:180-180, 1994
72.
72. Dhalla NS, Golfman L, Takeda S, et al. Evidence for the role of oxidative stress in acute ischemic heart disease: A brief review. Can J Cardiol15:587-587, 1999
73.
73. Grech ED, Dodd NJ, Jackson MJ, et al. Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am J Cardiol77:122-122, 1996
74.
74. Gushchin I, Petyaev I, Tsinkalovesky OKinetics of oxygen metabolism indices in the course of histamine secretion from rat mast cell. Agents Actions30:85-85, 1990
75.
75. Wolfreys K, Oliviera D.Alterations in intracellular reactive oxygen species generation and redox potential modulate mast cell function. Eur J Immunol27:297-297, 1997
76.
76. McNeill JH, Muschet LD. Histamine effects on cardiac contractility, phosphorylase and adenyl cyclase. J Mol Cell Cardiol4:611-611, 1972
77.
77. Schwartz LB, Metcalfe DD, Miller JS. Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med316:1622-1622, 1987
78.
78. Schwartz LB, Bradford TM. Regulation of tryptase from human lung mast cells by heparin stabilization of the active tetramer. J Biol Chem261:7372-7372, 1986
79.
79. DelBalzo UH, Levi R, Polley MJ. Cardiac dysfunction caused by purified human C3a anaphylotoxin. Proc Natl Acad Sci USA82:886-886, 1985
80.
80. Pinkard RN, Olson MS, Gliclas PC, et al. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after myocardial infarction. J Clin Invest56:740-740, 1975
81.
81. McManus LM, Kolb WP, Crawford MH, et al. Complement localization in ischemic baboon myocardium. Lab Invest48:346-346, 1983
82.
82. Dabbous MK, Tipton DA, Haney L.Mast cell mediated stimulation of collagen degradation by gingival fibroblasts. J Dent Res22:2005-2005, 1987
83.
83. Gruber BL, Schwartz LB, Ramamurthy NS, et al. Activation of latent rheumatoid synovial collagenase by human mast cell tryptase. J Immunol140:3936-3936, 1988
84.
84. Venge R, Olsson I.Cationic proteins of human granulocytes. Effects on the complement system and mediation of chemotactic activity. J Immunol115:1505-1505, 1975
85.
85. Seppa H, Vaananen K, Korhonen K.Effect of mast cell chymase of rat skin on intercellular matrix:a histochemical study. Acta Histochem64:64-64, 1979
86.
86. Mizutani, H, Schechter N, Lazarus G, et al. Rapid and specific conversion of precursor interleukin 1 beta (IL-I beta) to an active IL-I species by human mast cell chymase. J Exp Med174:821-821, 1991
87.
87. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-alpha and interleukin1 beta synergistically depress human myocardial functions. Crit Care Med27:1309-1309, 1999
88.
88. Valen G, Kaszaki J, Szabo I, et al. Histamine release and its effects in ischemia-reperfusion injury of isolated rat heart. Acta Physiol Scand150:413-413, 1994
89.
89. Rona G, Chappel CI, Kahn DS. The significance of factors modifying the development of isoprotemol induced myocardial infarction. Am heart J66:389-389, 1963
91. Bristow MR, Ginsburg R, Harrison DC. Histamine and human heart: The other receptor system. Am J Cardiol49:249-249, 1982
92.
92. McNeill JH, Vema SC. Histamine receptors in rabbit heart. Proc West Pharmacol Soc21:99-99, 1978
93.
93. Ley K.Histamine can induce leukocyte rolling in rat mesenteric venules. Am J Physiol267:H1017-H1017, 1994
94.
94. Weyrich AS, Ma SL, Lefer AM. Protective effects of a Pselectin monoclonal antibody in myocardial ischemia and reperfusion. Circulation86:180-180, 1992
95.
95. Mathews N, Naele ML, Jackson SK, Stark JM. Tumor killing by tumor necrosis factor: Inhibition by anaerobic conditions, free radical scavengers and inhibitors of arachidonate metabolism. Immunology62:153-153, 1987
96.
96. Yamuchi N, Kuriyama H, Watanabe N, et al. Intracelllar hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res49:1671-1671, 1989
97.
97. Murphy HS, Shayman JA, Till GO. Superoxide responses of endothelial cells to C5a and TNF: Divergent signal transduction pathways. Am J Physiol263:L51-L51, 1992
98.
98. Pogrebniak HW, Mathews WA, Pass HI. Reactive oxygen species and amplify macrophage tumor necrosis factor production. Surg Forum161:101-101, 1990
99.
99. Maury CP, Teppo AM. Circulating tumor necrosis factor alpha (cachectin) in myocardial infarction. J Int Med225:333-333, 1989
101. Patel VC, Yellon DM, Singh KJ, et al. Inhibition of nitric oxide limits infarct size in the in situ rabbit heart. Biochem Biophys Res Commun194:234-234, 1993
102.
102. Schulz R, Wambolt R.Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischemiareperfusion injury. Cardiovasc Res30:432-432, 1995
103.
103. Brady AJB, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocyte reduces their contractility in endotoxemia. Am J Physiol263:H1963-H1963, 1992
104.
104. Lamas S, Michel T, Brenner BM, Marsden PA. Nitric oxide synthesis in endothelial cells: Evidence for a pathway inducible by TNF. Am J Physiol261:C634-C634, 1991
105.
105. Busse R, Mulsch A.Induction of nitric oxide synthase by cytokines in vascular smooth cells. FEBS Lett257:87-87, 1990
106.
106. Oral H, Dorn GW, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-a in adult mammalian cardiac myocytes. J Biol Chem272:4836-4836, 1997
107.
107. Ohta H, Yatomi Y, Sweeney EA, et al. Possible role of sphingosine induction of apoptosis by tumour necrosis factor-a in human neutrophils. FEBS Lett355:267-267, 1994
108.
108. Edmunds NJ, Woodward B.Effects of tumour necrosis factor on the coronary circulation of rat isolated perfused heart:a potential role of thromboxane A2 and sphingosine. Br J Pharmacol124:493-493, 1998
109.
109. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor alpha in the adult mammalian heart. J Clin Invest92:2303-2303, 1993
110.
110. Arstall MA, Sawyer DB, Fukazowa R, Kelly RA. Cytokine mediated apoptosis in cardiac myocytes: The role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res85:829-829, 1999
111.
111. Roberts LJ, Lewis RA, Oates JA, Austen KF. Prostaglandin, thromboxane and 12-hydroxy-5, 8,10,14eicosatetraenoic acid production by ionophore stimulated rat serosal mast cells. Biochem Biophys Acta575:185-185, 1979
112.
112. Palmer RMJ, Stepney RJ, Higgs GA, Eakins KE. Chemokinetic activity of arachidonic acid lipoxygenase products on leukocytes of different species. Prostaglandins20:411-411, 1980
113.
113. Argenbright LW. Inflammatory mediators, cytokines and leukocyte adhesion in postcapillary venules. In Granger ND, Schmid-Schonbein WG (eds). Physiology and Pathophysiology of Leukocyte Adhesion. Oxford University Press, New York pp 171-185, 1995
114.
114. Lindbom L, Hedqvist P, Dahler SE, et al. Leukotriene B4 induces extravasation and migration of polymorphonuclear leukocytes in vivo. Acta Physiol Scand116:105-105, 1982
115.
115. Terashita Z, Fukui H, Hirata M, et al. Coronary vasoconstriction and PGI2 release by leukotrienes in isolated guinea pig hearts. Eur J Pharmacol73:357-357, 1981
116.
116. Pazenbaeck MJ, Kaley G.Leukotriene D4 reduces coronary blood flow in the anesthetized dog. Prostaglandins25:661-661, 1983
117.
117. Lefer AM, Campbell B, Scalia R, Lefer DJ. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion. Role of selectins. Circulation98:1322-1322, 1998
118.
118. Frangogiannis NG, Perrard JL, Mendoza LH, et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation98:687-687, 1998
120. Gaboury JP, Johnson B, Niu XF, Kubes P.Mechanisms underlying acute mast cell induced leukocyte rolling and adhesion in vivo. J Immunol154:804-804, 1995
121.
121. Ley K, Gachtgens P, Fennie C, et al. Lectin-like cell adhesion molecule mediates leukocyte rolling in mesenteric venules in vivo. Blood77:2553-2553, 1991
122.
122. VonAndrian UH, Chambers JD, McEvoy LM, et al. Two step model of leukocyte-endothelial cell interaction in inflammation: Distinct roles for LECAM-1 and the leukocyte 132 integrins in vivo. Proc Natl Acad Sci USA88:7538-7538, 1991
123.
123. Zimmerman GA, Prescott SM, Mclntyre TM. Endothelial cell interactions with granulocytes: Tethering and signaling molecules. Immunol Today13:93-93, 1992
124.
124. Patel KD, Lorant E, Jones DA, et al. Juxtacrine interactions of endothelial cells with leukocytes: Tethering and signaling molecules. Behring Inst Mitt92:144-144, 1993
125.
125. McPhail LC, DeChatelet LR, Shirley PS. Further characterization of NADPH oxidase activity of human polymorphonuclear leukocytes. J Clin Invest58:774-774, 1976
126.
126. Weiss SJ, Lamperts MB, Test ST. Long lived oxidants generated by human neutrophils: Characteristics and bioactivity. Science222:625-625, 1983
127.
127. Samuelsson B, Hammerstrom S, Murphy R, Borgeat P.Leukotrienes and slow reacting substance of anaphylaxis. Allergy35:375-375, 1980
128.
128. Lucchesi BR, Werns SW, Fentone JC. The role of neutrophils and free radicals in ischemic injury. J Mol Cell Cardiol21:1241-1241, 1989
129.
129. Hara M, Matsumori A, Ono K, et al. Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation100:1443-1443, 1999
130.
130. Ing DJ, Zang J, Dzau V, et al. Modulation of cytokine induced cardiomyocyte apoptosis by nitric oxide, Bak and Bcl-x. Circ Res84:21-21, 1999
131.
131. Carswell EA, Old IJ, Kassel RL, et al. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA72:3666-3666, 1975
132.
132. Baxter GT, Kuo RC, Jupp OJN, et al. Tumor necrosis factor-a mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. J Biol Chem274:9539-9539, 1999
133.
133. Krown KA, Yasui K, Brooken MJ. TNF alpha receptor expression in rat cardiomyocytes. TNF alpha inhibition by L-type Ca2+ current and Ca2+ transients. FEBS Lett376:24-24, 1995
134.
134. Torre-Aminone G, Kapadia S, Lee J.Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation92:1487-1487, 1995
135.
135. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J14:5579-5579, 1995
136.
136. Lin Y, Devin A, Rodriguez Y, Liu Z.Cleavage of death domain kinase RIP by caspase-8 promotes TNF-induced apoptosis. Genes Dev13:2514-2514, 1999
137.
137. Bradham CA, Qian T, Streetz K, et al. The mitochondrial transition is required for tumor necrosis factor apoptosis and cytochrome c release. Mol Cell Biol18:6353-6353, 1998
138.
138. Qin H, Srinivascula SM, Wu G, et al. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor-1. Nature399:549-549, 1999
139.
139. Nicholson DW, Ali A, Thronberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature376:37-37, 1995
140.
140. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP 323, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADPribose) polymerase. Cell81:801-801, 1995
141.
141. Cohon GM. Caspases: The executioners of apoptosis. Biochem J326:1-1, 1997
142.
142. Black SC, Huang JQ, Rezaiefar P, et al. Colocalization of the cysteine protease caspase-3 with apoptotic myocytes after in vivo myocardial ischemia and reperfusion in the rat. J Mol Cell Cardiol30:733-733, 1998
143.
143. Yue TL, Wang C, Romanic AM, et al. Staurosporineinduced apoptosis in cardiomyocytes: A potential role of caspase-3. J Mol Cell Cardiol39:495-495, 1998
144.
144. Yaoita H, Ogawa K, Meehara K, Maruyama Y.Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation97:276-276, 1998
145.
145. Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced bL ischemia and reperfusion in vivo. J Mol Cell Cardiol31:1709-1709, 1999
146.
146. Yaoita H, Ogawa K, Meehara K, Maruyama Y.Apoptosis in relevant clinical situations: Contribution of apoptosis in myocardial infarction. Cardiovasc Res45:630-630, 2000
147.
147. Panas D, Khadour FH, Szabo C, Schulz R.Proinflammatory cytokines depress cardiac efficiency by a nitric oxide dependent mechanism. Am J Physiol275:H1016-H1016, 1998
148.
148. Krown KA, Page MT, Nguyen C, et al. Tumour necrosis factor alpha-induced apoptosis in cardiac myocytes: Involvement of sphingolipid signaling cascade in cardiac cell death. J Clin Invest98:2864-2864, 1996
149.
149. Bielawska AE, Shapiro JP, Jiang L, et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol151:1257-1257, 1997
150.
150. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor-alpha induced apoptosis in cardiomyocytes: Involvement of sphingolipid signaling cascade in cardial cell death. J Clin Invest98:2854-2854, 1996
151.
151. Hogaboam CM, Befus AD, Wallace JL. Modulation of rat mast cell reactivity by IL-I beta. Divergent effects on nitric oxide and platelet activating factor release. J Immunol151:3767-3767, 1993
152.
152. Lee JC, Badger AM, Griswold DE, et al. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann NY Acad Sci696:149-149, 1993
154. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac functions after myocardial ischemia and reperfusion. Circulation99:1685-1685, 1999
155.
155. Barancik M, Htun P, Strohm C, et al. Inhibition of the cardiac p38-MAPK pathway by SB 203580 delays ischemic cell death. J Cardiovasc Pharmacol35:474-474, 2000
156.
156. Kimata M, Inagaki M, Kato T, et al. Roles of mitogenactivated protein kinase pathways for mediator release from human cultured mast cells. Biochem Pharmacol60:589-589, 2000
157.
157. Yue TL, Ma XL, Wang X, et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res82:166-166, 1998
158.
158. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature372:739-739, 1994
159.
159. Quillet-Mary A, Jaffrezon JP, Mansat V, et al. Implication of mitochondrial hydrogen peroxide generation in ceramide induced apoptosis. J Biol Chem272:21388-21388, 1997
160.
160. Maulik N, Yoshida T, Das DK. Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis. Free Rad Biol Med24:869-869, 1998
161.
161. Hirose K, Longo DL, Oppenheim JJ, Matsushima K.Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin1, tumor necrosis factor, selected anticancer drugs and ionizing radiations. FASEB J7:361-361, 1993
162.
162. Sandstorm PA, Buttke TM. Autocrine production of extracellular catalase prevents apoptosis of the human CEM T-cell line in serum free medium. Proc Natl Acad Sci USA90:4708-4708, 1993
163.
163. Li C, Browder W, Kao RL. Early activation of transcription factor NF-kB during ischemia in perfused rat heart. Am J Physiol276:H543-H543, 1999
164.
164. Xie QW, Kashiwabara Y, Nathan C.Role of transcription factor NF-kB/Rel in induction of nitric oxide synthase. J Biol Chem269:4705-4705, 1994
165.
165. Zweier JL, Wang P, Kuppusamy P.Direct measurement of nitric oxide generation in the ischemic heart using electron paramagnetic resonance spectroscopy. J Biol Chem270:304-304, 1995
166.
166. Nagata S.Apoptosis by death factor. Cell88:355-355, 1997
167.
167. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation74:1124-1124, 1986
168.
168. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in the rat heart. Am J Physiol263:H1107-H1107, 1992
169.
169. Liu GS, Thornton J, Van Winckle DM, et al. Protection against infarction afforded by preconditioning is mediated by A, adenosine receptors in rabbit heart. Circulation84:350-350, 1991
170.
170. Vahlhaus C, Schulz R, Post H, et al. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res79:407-407, 1996
171.
171. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with preconditioning. Circulation82:609-609, 1990
172.
172. Ikonomidis JS, Shirai T, Weisel RD, et al. Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Am J Physiol272:H1220-H1220, 1997
173.
173. Hu K, Nattel S.Mechanisms of ischemic preconditioning in rat hearts. Involvement of 1xB-adrenoceptors, pertusis toxin sensitive G proteins and protein kinase C. Circulation92:2259-2259, 1995
174.
174. Tosaki A, Behjet N, Engelman DT, et al. Alpha-I adrenergic receptor induced preconditioning in isolated working rat hearts. J Pharmacol Exp Ther273:689-689, 1995
175.
175. Sharma A, Singh M.The possible role of adrenergic component in ischemic preconditioning. Meth Find Exp Clin Pharmacol19:L493-L493, 1997
176.
176. Goto M, Liu Y, Yang X, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res77:611-611, 1995
177.
177. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with Al selective adenosine analogues protects the heart against infarction. Circulation85:659-659, 1992
178.
178. Schultz JEJ, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res78:1100-1100, 1996
179.
179. Hide EJ, Piper J, Thiemermann C.Endothelin-1-induced reduction of myocardial infarct size by activation of ATPsensitive potassium channels in a rabbit model of myocardial ischemia and reperfusion. Br J Pharmacol116:2597-2597, 1995
180.
180. Walker DM, Pasini E, Kucukoglu S, et al. Heat stress limits infarct size in the isolated perfused rabbit heart. Cardiovasc Res27:962-962, 1993
181.
181. Szekeres L, Papp GJ, Szilvassy Z, et al. Moderate stress by cardiac pacing may induce both short term and long term cardioprotection. Cardiovasc Res27:593-593, 1993
182.
182. Howard G, Geoghegan TE. Altered cardiac tissue gene expression during acute hypoxic exposure. Mol Cell Biochem69:155-155, 1986
183.
183. Shizukuda Y, Mallet RT, Lee S, Downey HF. Hypoxic preconditioning of ischemic canine myocardium. Cardiovasc Res26:534-534, 1992
184.
184. Tuijl MJ, Ven Bergenen Henegouwen PM, Van Wijk R, Verkleij AJ. The isolated neonatal rat cardiomyocyte used as in vitro model for ischemia: Induction of the 68kDa heat shock protein. Biochim Biophys Acta1091:278-278, 1991
185.
185. Simkhovich BZ, Przyklenk K, Kloner RA. Role of protein kinase C as a cellular mediator of ischemic preconditioning. A critical review. Cardiovasc Res40:9-9, 1988
186.
186. Kawata H, Yoshida K, Kawamoto A, et al. Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase C epsilon in the rat ischemic myocardium. Cir Res88:696-696, 2001
187.
187. Liu H, McPherson BC, Yao Z.Preconditioning attenuates apoptosis and necrosis: Role of protein kinase C epsilon and delta isoforms. Am J Physiol281:H404-H404, 2001
188.
188. Xuan Y, Tang X, Banerjee S, et al. Nuclear factor-iB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res84:1095-1095, 1999
189.
189. Baines CP, Wang L, Cohen MV, Downey JM. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol30:383-383, 1998
190.
190. Vahlhaus C, Schulz R, Post H, et al. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol30:197-197, 1998
191.
191. Yin T, Sandhu G, Wolfgang CD, et al. Tissue specific pattern of stress kinase activation in ischemic-reperfused heart and kidney. J Biol Chem272:19943-19943, 1997
192.
192. Dana A, Skarli M, Papakrivopoulou J, Yellon DM. Adenosine A, receptor induced delayed preconditioning in rabbits: Induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase-and protein kinase C-dependent mechanism. Circ Res86:989-989, 2000
193.
193. Nakano A, Baines CP, Kim SO, et al. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: Evidence for involvement of p38 MAPK. Circ Res86:144-144, 2000
194.
194. Fryer RM, Eells JT, Hsu AK, et al. Ischemic preconditioning in rats: Role of mitochondrial KATP channel in preservation of mitochondrial function. Am J Physiol278:H305-H305, 2000
195.
195. Nakai Y, Horimoto H, Mieno S, Sasaki S.Mitochondrial ATP-sensitive potassium channel plays a dominant role in ischemic preconditioning of rabbit heart. Eur Surg Res33:57-57, 2001
196.
196. Barry WH. Calcium and ischemic injury. Trends Cardiovasc Med1:162-162, 1991
197.
197. Zucchi R, Ronca-Testoni S, Yu G, et al. Postischemic changes in cardiac sarcoplasmic reticulum Ca2+ channels. A possible mechanism of ischemic preconditioning. Cir Res76:1049-1049, 1995
198.
198. Weiss RG, de Albuquerque CP, Vandegaer K, et al. Attenuated glycogenolysis reduced glycolytic catabolite accumulation during ischemia in ischemic preconditioned rat hearts. Circ Res79:435-435, 1996
199.
199. Lawson CS, Downey JM. Preconditioning: State of the art of myocardial protection. Cardiovasc Res27:542-542, 1993
200.
200. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res66:913-913, 1990
201.
201. Kaur H, Parikh V, Sharma A, Singh M.Effect of amiloride a Na+/H+ exchange inhibitor on cardioprotective effect of ischemic preconditioning: Possible involvement of resident cardiac mast cells. Pharmacol Res36:95-95, 1997
202.
202. Parikh V, Singh M.Resident cardiac mast cells and cardioprotective effect of ischemic preconditioning in isolated rat heart. J Cardiovasc Pharmacol30:149-149, 1997
203.
203. Parikh V, Singh MP. Possible role of adrenergic component and cardiac mast cell degranulation in preconditioning-induced cardioprotection. Pharmacol Res40:129-129, 1999
204.
204. Parikh V, Singh M.Possible role of nitric oxide and mast cells in endotoxin-induced cardioprotection. Pharmacol Res43:39-39, 2001
205.
205. Sharma A, Singh M.Molecular and cellular mechanism of cardioprotective effect of ischemic preconditioning. Thesis Punjabi University Patiala, India, 2001
206.
206. Linden J.Cloned adenosine A3 receptors: Pharmacological properties, species difference and receptor functions. Trends Pharmacol Sci15:598-598, 1994
207.
207. Wang P, Downey JM, Cohen MV. Mast cell degranulation does not contribute to ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol91:458-458, 1996
208.
208. Humphreys RA, Kane KA, Parratt JR. Lack of involvement of mast cell degranulation in antiarrhythmic effect of preconditioning in rats. J Cardiovas Pharmacol31:418-418, 1998
209.
209. White JR, Ishizaka T, Ishizaka K, Shauji R.Direct demonstration of increase intracellular concentration of free calcium as measured by quin-2 in stimulated rat peritoneal mast cells. Proc Natl Acad Sci USA81:3978-3978, 1984
210.
210. Theoharides TC, Sieghart W, Cirengaard P, Douglas WW. An antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science207:80-80, 1980
211.
211. Liao L, Granger DN. Role of mast cells in oxidised lowdensity lipoprotein induced microvascular dysfuction. Am J Physiol271:H1795-H1795, 1996
212.
212. Costa JJ, Harris AG, Delano FA, et al. Mast cell degranulation and parenchymal cell injury in the rat mesentery. Microcirculation6:237-237, 1999
213.
213. Jaggi AS, Sharma A, Singh M. Role of resident cardiac mast cells in ischemia-reperfusion induced myocardial injury. Thesis Punjabi University Patiala, India, 2000
214.
214. DoBoer LVW, Nosta JJ, Johnson HG, Kloner RA. Reduction of myocardial infarct size by Lodoxamide (U42-585E), a mast cell inhibitor (Abstract). Clin Res29:A185-A185, 1981
215.
215. Queralt M, Brazis P, Merlos M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-ax release from dispersed canine skin mast cells and the human mast cell line HMC-1. 49:355-355, 2000
216.
216. Crivellato E, Candussioi L, Decorti G, et al. Adriamycin binds to the matrix of secretory granules during mast cell exocytosis. Biotech Histochem72:111-111, 1997
217.
217. Bristow MR, Sageman WS, Scott RH, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog. The cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol2:487-487, 1980
218.
218. Juniper EF, Cartier A, Trebilcock AL, et al. Effects of oxatomide compared with chlorpheniramine in allergic rhinoconjuctivitis. Clin Allergy11:61-61, 1981
219.
219. Masini E, Gianella G, Bianchi S, Mannaioni PF. Histamine and lactate dehydrogenase (LDH) release in ischemic myocardium of the guinea pig. Agents and Actions20:281-281, 1987
220.
220. Jacobi HH, Skov PS, Poulsen LK, et al. Histamine and tryptase in nasal lavage fluid after allergen challenge: Effect of 1 week pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol103:768-768, 1999
221.
221. Miller TR, Writte DG, Ireland LM, et al. Analysis of apparent non-competitive responses to competitive H,histamine receptor antagonists in fluorescent imaging plate reader based calcium assays. J Biomol Screen4:249-249, 1999
222.
222. Blokland A, Scholtissen B, Vermeeren A, Ramaekers J. Dissociable effects of histamine H, antagonists on reaction-time performance in rats. Pharmacol Biochem Behav70:427-427, 2001
223.
223. Suresh PS, Sharma A, Singh M. Implication of H, receptors and resident cardiac mast cells in ischemia-reperfusion induced myocardial injury. Thesis Punjabi University Patiala, India, 2002
224.
224. Schulze W, Fu ML. Localization of alpha 1-adrenoceptors in rat and human hearts by immunocytochemistry. Mol Cell Biochem163-64:159-159, 1996
225.
225. Exton JH. Molecular mechanisms involved in x adrenergic responses. Mol Cell Endocrin23:233-233, 1981
226.
226. Vanhoutte PM, Rimele TJ. Calcium and ox adrenoceptors in activation of vascular smooth muscles. J Cardiovasc Pharmacol4:S280-S280, 1982
227.
227. Kanno T, Cachrane DE, Dougas WW. Exocytosis (secretory granule extrusion) induced by injection of calcium into mast cells. Can J Physiol Pharmacol51:1001-1001, 1973
228.
228. Foreman JC, Monger JL, Gompers BD. Calcium ionophores and movement of calcium ions following the physiological stimulus to a secretory process. Nature245:249-249, 1973
229.
229. Moroni F, Fantozzi R, Masini E, Mannaioni PF. The modulation of histamine release by alpha-adrenoceptors: Evidences in murine neoplastic mast cells. Agents Actions7:57-57, 1977
230.
230. Nichols AJ, Sulpizio AC, Ashoton DJ, et al. In vitro pharmacologic profile of novel beta adrenoceptor antagonist and vasodilator cavedilol. Pharmacology39:327-327, 1989
231.
231. Cargnoni A, Claudio C, Bernocchi P, et al. Reduction of oxidative stress by carvedilol: Role of maintainance of ischemic myocardium viability. Circ Res47:556-556, 2000
232.
232. Book WM. Carvedilol: A nonselective beta blocking agent with antioxidant properties. Congest Heart Fail8:173-173, 2002
233.
233. Nichols AJ, Gellai M, Ruffolo RRJ. Studies on mechanism of arterial vasodilation produced by novel antihypertensive agonist carvedilol. Fund Clin Pharinacol5:25-25, 1991
234.
234. Karmazyn M, Moffat MP. Role of Na+/H+ exchange in cardiac physiology and pathophysiology: Mediation of myocardial reperfusion injury by the pH paradox. Cardiovasc Res27:915-915, 1993
235.
235. Ladzunski M, Frelin C, Vigne P.The sodium/hydrogen exchange system in cardiac cells: Its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J Mol Cell Cardiol17:1209-1209, 1985
236.
236. Meng HP, Lonsberry BR, Pierce GN. Influence of perfusate on the postischemic recovery of cardiac contractile function: Involvement of sodium hydrogen exchange. J Pharmacol Exp Ther258:772-772, 1991
237.
237. Piwnica-Worms D, Jacob R, Shigeto N, et al. Na+/H+ exchange in cultured chick heart cells: Secondary stimulation of electrogenic transport during recovery from intracellular acidosis. J Mol Cell Cardiol18:1109-1109, 1986
238.
238. Dennis SC, Coetzee WA, Cragoe EJ, Opie LH. Effects of proton buffering and of amiloride derivatives on reperfusion arrhythmias in isolated rat hearts: Possible evidence for an arrhythmogenic role of Na+-H+ exchange. Circ Res66:1156-1156, 1990
239.
239. Fossard N, Amella M, Landry Y.Sodium-potassium ATPase and immunological histamine release. Biochem Pharmacol32:3259-3259, 1983
240.
240. Knudsen T, Bertelsen H, Johansen T.Ouabain enhancement of compound 48/80 induced histamine secretion from rat peritoneal mast cells: Dependence on extracellular sodium. Pharmacol Toxicol70:412-412, 1992
241.
241. Linnebjerg H, Hansen HS, Jensen B.Inhibition by amiloride and by Na+ deplection of A23187-stimulated arachidonic acid and histamine release from rat mast cells. FEBS Lett240:167-167, 1988
242.
242. Seiler SM, Cragoe EJ, Jones LR. Demonstration of Na+/H+ exchange activity in purified canine cardiac sarcolemmal vesicles. J Biol Chem260:4869-4869, 1985
243.
243. Vigne P, Frelin C, Cragoe EJ Jr, Lazdunski M.Ethylisopropyl amiloride: A new and highly potent derivative of ameloride for the inhibition of the Na+/H+ exchange system in various cell types. Biochem Biophys Res Commun116:86-86, 1983
244.
244. Sharma A, Singh M.Effect of ethylisopropyl amiloride, a Na+-H+ exchange inhibitor, on cardioprotective effect of ischemic and angiotensin preconditioning. Mol Cell Biochem214:31-31, 2000
245.
245. Deshpande SB, Fukuda A, Nishino H.3-Nitropropionic acid increases intracellular Ca2+ in cultured astocytes by reverse operation of Na+-Ca2+ exchanger. Exp Neurol145:38-38, 1997
246.
246. Kamboj R, Sharma A, Singh M. Role of calcium in the cardioprotective effect of ischemic preconditioning. Thesis Punjabi University Patiala, India, 1999
247.
247. Nayler WG, Poole-Wilson PA. Calcium antagonists definition and mode of action. Basic Res Cardiol76:1-1, 1981
248.
248. Ma J.Block by ruthenium red of ryanodine-activated calcium release channel of skeletal muscle. J Gen Physiol102:1031-1031, 1993
249.
249. Ursell PC, Mayes M.Anatomic distribution of nitric oxide synthase in the heart. Int J Cardiol50:217-217, 1995
250.
250. Coleman JW. Nitric oxide: A regulator of mast cell activation and mast cell mediated inflammation. Clin Exp Immunol129:4-4, 2002
251.
251. Masini E, Gambassi F, Pistelli A, et al. Correlation between nitric oxide synthesis and histamine release in mast cells from spontaneously hypertensive rats: Influence of aging. Arch Allergy Immunol99:404-404, 1992
252.
252. Masini E, DiBello MG, Pistelli A, et al. Generation of nitric oxide from nitrovasodilators modulates the release of histamine from mast cells. J Physiol Pharmacol45:41-41, 1994
253.
253. Masini E, Bianchi S, Mugnal L, et al. The effect of nitric oxide generators on ischemia-reperfusion injury and histamine release in isolated perfused guinea pig heart. Agents Action33:53-53, 1991
254.
254. Mannaioni PF, Masini E.The release of histamine by free radicals. Free Rad Biol Med5:177-177, 1988
256. Schulz R, Nava E, Moncda S.Induction and potential biological relevance of a Ca2+ independent nitric oxide synthase in the myocardium. Br J Pharmacol105:575-575, 1992
257.
257. McKenna TM, Li S, Tsao S.PKC mediates LPS and phorbol-induced cardiac cell nitric oxide synthase activity and hypocontractility. Am J Physiol269:H1891-H1891, 1995
258.
258. Song W, Furman BL, Parratt JR. Attenuation by dexamethasone of endotoxin protection against ischemiainduced ventricular arrhythmias. Br J Pharmacol113:1083-1083, 1994
259.
259. Yang BC, Chen LY, Saldeen TG, Mehta JL. Reperfusion injury in the endotoxin-treated rat heart: Reevaluation if the role of nitric oxide. Br J Pharmacol120:305-305, 1997
260.
260. Iyenger R, Stuehr DJ, Marletta MA. Macrophage synthesis of nitrite, nitrate and N-nitrosamines: Precursors and role of the respiratory burst. Proc Natl Acad Sci USA84:6369-6369, 1987
261.
261. Shichijo M, Inagaki N, Kimata M, et al. Role of 3'-5'adenosine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells. J Allergy Clin Immunol103:S421-S421, 1999
262.
262. Dent G, Giembycz MA, Evans PM, et al. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: Interaction with beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther271:1167-1167, 1994
264. Brzezinska-Blaszczyk E, Forczmanski M, Pletrazak A.The action of tumor necrosis factor-alpha on rat mast cells. J Interferon Cytokine Res20:377-377, 2001
265.
265. Saini HK, Sharma A, Singh M. Resident cardiac mast cells and ischemia-reperfusion induced apoptotic and necrotic myocardial cell death. Thesis Punjabi University Patiala, India, 2002
266.
266. Takahashi S, Keto Y, Fujita T, et al. FR 167653, a p38 mitogen activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. J Pharmacol Exp Ther296:48-48, 2001
